Could Anemia Increase the Risk of Developing Dementia?

Why It Matters

Anemia is a common, treatable condition, so identifying it as a potential modifiable risk factor could inform early dementia‑prevention strategies and improve patient monitoring.

Key Takeaways

• 2,282 Swedish seniors tracked for up to 16 years
• Anemia increased dementia risk by 66% versus normal hemoglobin
• Risk amplified when anemia paired with high Alzheimer’s biomarkers
• Association stronger in men; absent in APOE‑ε4 carriers
• Anemia may serve as a modifiable dementia risk marker

Pulse Analysis

Anemia, affecting roughly one in ten older adults, reduces the oxygen‑carrying capacity of blood and has been linked to a spectrum of chronic diseases. The new Swedish National Study on Aging and Care in Kungsholmen followed 2,282 participants aged 60 and older for up to 16 years, measuring baseline hemoglobin and a panel of Alzheimer’s‑related blood biomarkers. By excluding individuals with dementia at entry, the researchers created a prospective cohort that could isolate the long‑term cognitive consequences of low hemoglobin levels.

The analysis revealed that participants with anemia faced a 66 % higher incidence of dementia compared with those whose hemoglobin was within normal limits. This risk intensified when anemia co‑existed with elevated plasma pTau217 or neurofilament light chain (NfL), suggesting an additive interaction between oxygen deficiency and neurodegenerative pathology. Notably, the association was driven primarily by men; women showed a weaker link, and carriers of the APOE‑ε4 allele did not exhibit increased risk. These sex‑specific patterns hint at hormonal or genetic modifiers that may influence how systemic iron deficiency impacts brain health.

From a clinical perspective, anemia is readily detectable through routine complete‑blood‑count tests and, in many cases, correctable with iron, vitamin B12 or erythropoietin therapy. If future interventional trials confirm a causal pathway, treating anemia could become a low‑cost strategy to blunt cognitive decline in aging populations. However, the observational nature of the study, its homogeneous Swedish cohort, and reliance on baseline biomarker snapshots limit definitive conclusions. Researchers therefore advocate larger, multi‑ethnic trials that track hemoglobin and biomarker trajectories over time to determine whether correcting anemia truly modifies dementia risk.